Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer-Reference-Cited by-同舟云学术

Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer

Published:2023-08 Issue: Volume:91 Page:117384
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Jia Tingting,Miao Ruoyang,Zhang Jiankang,Zhu Huajian,Zhang Chong,Zeng Linghui,Zhao Yanmei,Cheng Weiyan,Shao Jiaan

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference30 articles.

1. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions;Chen;Signal Transduct Target Ther,2023

2. Targeting hypoxia to improve non-small cell lung cancer outcome;Salem;Jnci-J Natl Cancer Inst,2018

3. Hypoxia in lung cancer management: a translational approach;Ancel;Cancers,2021

4. Targeting Tumor Hypoxia with hypoxia-activated prodrugs;Yeh;J Clin Oncol,2015

5. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers;Le;Clin Cancer Res,2006

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

2. In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer;Biomedicines;2023-07-17